Compound E, chemically designated as 209986-17-4, represents a significant exploration within the field of Alzheimer's illness research. This γ-secretase inhibitor was initially developed as a promising therapeutic treatment aimed at reducing the synthesis of amyloid-beta peptides, which are believed to be critical contributors to the formation of